Overview

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Status:
Completed
Trial end date:
2020-12-04
Target enrollment:
Participant gender:
Summary
This is a 2-part, study to determine the safety, tolerability and pharmacokinetics of oral dabrafenib in children and adolescent subjects with advanced BRAF V600 mutation-positive solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Novartis Pharmaceuticals
Treatments:
Dabrafenib